Clinically, MAO inhibition is used to treat Parkinson’s disease anxiety and depression (although medications targeting MAO-B are preferred) (Edmondson et al., 2009; Thomas et al., 2015). This evidence concerns the gene MAOB and depressive symptom measurement.